EP
ACAD icon

Essential Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Essential Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
566
-25
-4% -$550 0.01% 1043
2026
Q1 		$13.2K Sell
591
-177
-23% -$4.23K ﹤0.01% 1114
2025
Q4 		$20.5K Sell
768
-544
-41% -$13K 0.01% 897
2025
Q3 		$28K Buy
1,312
+736
+128% +$17.4K 0.01% 785
2025
Q2 		$12.4K Buy
+576
New +$10.7K 0.01% 788

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Essential Partners's ACAD Position: Q2 2026 in Review

Essential Partners reduced its Acadia Pharmaceuticals (ACAD) stake by 4.2% in Q2 2026, selling an estimated $550 and leaving 566 shares worth $14.3K. The position accounts for 0.01% of the portfolio, ranked #1043.

Essential Partners first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. The position peaked at $28K in Q3 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Essential Partners held 566 shares of Acadia Pharmaceuticals worth $14.3K as of Q2 2026.
  • Essential Partners sold 25 Acadia Pharmaceuticals shares in Q2 2026, an estimated $550.
  • Acadia Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1043 holding.
  • Essential Partners first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Acadia Pharmaceuticals position peaked at $28K in Q3 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.